Skip to main content
SI

SemPresto, Inc

SemPresto develops ultra-portable, attachable autoinjector platforms designed to improve patient adherence to carrying emergency rescue medications. The initial product is an epinephrine autoinjector that seamlessly integrates with standard phone cases to ensure accessibility during anaphylaxis events. The company plans to expand its platform to deliver other critical rescue drugs for conditions like seizures and opioid overdose.

Founded 20241100+ followers
Updated 3 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Many individuals at risk of anaphylaxis and other emergency conditions do not consistently carry bulky, traditional autoinjectors, leading to delayed administration of life-saving medications during critical events. This lack of accessibility can result in worsened health outcomes, increased hospitalizations, and even fatalities.

Solution

SemPresto is developing an ultra-portable autoinjector designed to attach seamlessly to any standard smartphone case, ensuring that emergency rescue medications are always readily available. The slim, discreet design promotes consistent carry, addressing the challenge of bulky devices being left behind. A simple two-step unlock mechanism ensures safety while allowing for quick deployment when needed. SemPresto's initial product focuses on epinephrine delivery for anaphylaxis, with future products planned for conditions such as seizures, hypoglycemia, and opioid overdose. A companion app provides training resources, refill reminders, and emergency contact support to improve patient outcomes.

Target Audience

The primary target audience includes individuals with severe allergies at risk of anaphylaxis, as well as those susceptible to seizures, hypoglycemia, and opioid overdose, and their caregivers.

Features

  • Ultra-portable design with a slim profile (3/8" thickness) for attachment to any cell phone case
  • Two-step unlock mechanism for safe and rapid deployment
  • Companion app with training resources, refill reminders, and emergency contact support
  • Developing product pipeline for anaphylaxis (epinephrine), seizures (midazolam), hypoglycemia (glucagon), and opioid overdose (naloxone)
  • Compatible with standard phone cases without obstructing the camera or limiting phone functionality
This profile is AI-generated and may contain inaccuracies.